Premium
Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease
Author(s) -
Vergallo Andrea,
Mégret Lucile,
Lista Simone,
Cavedo Enrica,
Zetterberg Henrik,
Blennow Kaj,
Vanmechelen Eugeen,
De Vos Ann,
Habert MarieOdile,
Potier MarieClaude,
Dubois Bruno,
Neri Christian,
Hampel Harald
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.03.009
Subject(s) - medicine , apolipoprotein e , amyloidosis , cohort , positron emission tomography , alzheimer's disease neuroimaging initiative , disease , receiver operating characteristic , amyloid (mycology) , alzheimer's disease , confidence interval , oncology , pathology , nuclear medicine
Blood‐based biomarkers of pathophysiological brain amyloid β (Aβ) accumulation, particularly for preclinical target and large‐scale interventions, are warranted to effectively enrich Alzheimer's disease clinical trials and management. Methods We investigated whether plasma concentrations of the Aβ 1–40 /Aβ 1–42 ratio, assessed using the single‐molecule array (Simoa) immunoassay, may predict brain Aβ positron emission tomography status in a large‐scale longitudinal monocentric cohort (N = 276) of older individuals with subjective memory complaints. We performed a hypothesis‐driven investigation followed by a no‐a‐priori hypothesis study using machine learning. Results The receiver operating characteristic curve and machine learning showed a balanced accuracy of 76.5% and 81%, respectively, for the plasma Aβ 1–40 /Aβ 1–42 ratio. The accuracy is not affected by the apolipoprotein E ( APOE ) ε4 allele, sex, or age. Discussion Our results encourage an independent validation cohort study to confirm the indication that the plasma Aβ 1–40 /Aβ 1–42 ratio, assessed via Simoa, may improve future standard of care and clinical trial design.